false 1 September 2024 OC413389 2024-09-01 2025-08-31 OC413389 2024-08-31 OC413389 2025-08-31 OC413389 frs102-bus:FRS102 2024-09-01 2025-08-31 OC413389 frs102-bus:LimitedLiabilityPartnershipLLP 2024-09-01 2025-08-31 OC413389 frs102-bus:FullAccounts 2024-09-01 2025-08-31 OC413389 frs102-bus:AuditExempt-NoAccountantsReport 2024-09-01 2025-08-31 OC413389 2023-09-01 2024-08-31 OC413389 2023-08-31 OC413389 2024-08-31 OC413389 frs102-core:CurrentFinancialInstruments 2025-08-31 OC413389 frs102-core:CurrentFinancialInstruments 2024-08-31 OC413389 frs102-core:Non-currentFinancialInstruments 2025-08-31 OC413389 frs102-core:Non-currentFinancialInstruments 2024-08-31 OC413389 frs102-bus:Director1 2024-09-01 2025-08-31 xbrli:pure iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares

| Registered number:
| OC413389

| Abby Pharma (U.K) LLP |
| Unaudited Accounts |
| for the Year Ended |
| 31 August 2025 |

Abby Pharma (U.K) LLP Balance Sheet as at 31 August 2025
| Notes |  | 2025 £ |  | 2024 £
--- | --- | --- | --- | --- | ---
Current Assets |  |  |  |  |
Debtors |  | 2,169,831 |  | 2,049,866 |
Cash at bank and in hand |  | 1,270,541 |  | 996,526 |
|  | 3,440,372 |  | 3,046,392 |
Creditors falling due within one year |  | (1,053,506) |  | (1,395,619) |
Net Current Assets / (Liabilities) |  |  | 2,386,866 |  | 1,650,773
Creditors falling due after more than one year |  |  | (0) |  | (3,266)
Net Assets Attributable to Members |  |  | 2,386,866 |  | 1,647,507
Represented by: |  |  |  |  |
Loans and other debts due to members within one year
Members' capital classified as a liability | 3 |  | 2,278,488 |  | 1,539,129
|  |  | 2,278,488 |  | 1,539,129
. |  |  |  |  |
Members' other interests
Members' capital classified as a equity | 3 |  | 108,378 |  | 108,378
|  |  | 2,386,866 |  | 1,647,507
. |  |  |  |  |
Total members' interests
Loans and other debts due to members |  |  | 2,278,488 |  | 1,539,129
Members' other interests |  |  | 108,378 |  | 108,378
|  |  | 2,386,866 |  | 1,647,507

Abby Pharma (U.K) LLP
Balance Sheet
as at 31 August 2025

These accounts have been prepared and delivered in accordance with the provisions applicable to LLPs subject to the small LLPs regime.

The members have not delivered a copy of the LLP's Profit and Loss account as permitted by s444(5A) of the Companies Act 2006 (as applied to LLPs).

The members acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 (as applied to LLPs) with respect to accounting records and the preparation of accounts.

For the year ended 31 August 2025 the LLP was entitled to exemption under section 477 of the Companies Act 2006 (as applied to LLPs) relating to small LLPs.

The financial statements were approved by the members and signed on their behalf by:

.........................................................

Approved by members on 2 June 2026

Meniland Group Ltd

Designated Member

Abby Pharma (U.K) LLP

Registered number: OC413389 (England and Wales)

Abby Pharma (U.K) LLP
Notes to the Accounts
for the year ended 31 August 2025

1. | Accounting Policies
--- | ---
| Basis of preparation These financial statements have been prepared under the historic cost convention in accordance with the accounting policies set out below and with section 1A of FRS 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland, the Companies Act 2006 and the Statement of Recommended Practice "Accounting by Limited Liability Partnerships". These financial statements reflect the results of the LLP for the year ended 31 August 2025.

| Turnover
| Turnover represents amounts due in respect of trade plus indirect taxes and fees during they year

| Tax provisions
| Taxation on the profits of the LLP is solely the liability of individual members. Therefore, neither income tax nor deferred tax arising in respect of the LLP's profit is included in these financial statements.

2. | Employees
--- | ---
|  | 2025 |  | 2024
| Average number of employees during the period | 0 |  | 0

3. Members' Interests
| Members capital classed as equity |  | Other reserve |  | Total 2025 |  | Total 2024
| £ |  | £ |  | £ |  | £
Brought Forward | 108,378 |  | 1,718,444 |  | 1,647,507 |  | 2,025,243
Profit (loss) for period available for discretionary division among members | - |  | 739,359 |  | 739,359 |  | (377,736)
Members' interest after profit (loss) for period | 108,378 |  | 2,457,803 |  | 2,386,866 |  | 1,647,507
Other divisions of profits (losses) | - |  | - |  | - |  | -
Balance carried forward | 108,378 |  | 2,457,803 |  | 2,386,866 |  | 1,647,507